197 related articles for article (PubMed ID: 35501304)
1. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML.
Yilmaz M; Kantarjian H; Short NJ; Reville P; Konopleva M; Kadia T; DiNardo C; Borthakur G; Pemmaraju N; Maiti A; Jabbour E; Jain N; Issa G; Takahashi K; Sasaki K; Ohanian M; Pierce S; Tang G; Loghavi S; Patel K; Wang SA; Garcia-Manero G; Andreeff M; Ravandi F; Daver N
Blood Cancer J; 2022 May; 12(5):77. PubMed ID: 35501304
[TBL] [Abstract][Full Text] [Related]
2. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory
Short NJ; Daver N; Dinardo CD; Kadia T; Nasr LF; Macaron W; Yilmaz M; Borthakur G; Montalban-Bravo G; Garcia-Manero G; Issa GC; Chien KS; Jabbour E; Nasnas C; Huang X; Qiao W; Matthews J; Stojanik CJ; Patel KP; Abramova R; Thankachan J; Konopleva M; Kantarjian H; Ravandi F
J Clin Oncol; 2024 May; 42(13):1499-1508. PubMed ID: 38277619
[TBL] [Abstract][Full Text] [Related]
3. Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors.
Short NJ; Nguyen D; Ravandi F
Blood Cancer J; 2023 Sep; 13(1):142. PubMed ID: 37696819
[TBL] [Abstract][Full Text] [Related]
4. Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy.
Weng G; Huang J; An N; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; He X; Jin H; Liu Q; Du X
Cancer Med; 2024 Jan; 13(2):e6885. PubMed ID: 38334500
[TBL] [Abstract][Full Text] [Related]
5. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
[TBL] [Abstract][Full Text] [Related]
6. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.
Maiti A; DiNardo CD; Daver NG; Rausch CR; Ravandi F; Kadia TM; Pemmaraju N; Borthakur G; Bose P; Issa GC; Short NJ; Yilmaz M; Montalban-Bravo G; Ferrajoli A; Jabbour EJ; Jain N; Ohanian M; Takahashi K; Thompson PA; Loghavi S; Montalbano KS; Pierce S; Wierda WG; Kantarjian HM; Konopleva MY
Blood Cancer J; 2021 Feb; 11(2):25. PubMed ID: 33563904
[No Abstract] [Full Text] [Related]
7. Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
Ngo D; Tinajero J; Li S; Palmer J; Pourhassan H; Aribi A; Nakamura R; Stein A; Marcucci G; Salhotra A; Sandhu K; Pullarkat V; Ball B; Koller P
Leuk Lymphoma; 2024 Mar; 65(3):372-377. PubMed ID: 38164785
[TBL] [Abstract][Full Text] [Related]
8. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
Kadia TM; Reville PK; Borthakur G; Yilmaz M; Kornblau S; Alvarado Y; Dinardo CD; Daver N; Jain N; Pemmaraju N; Short N; Wang SA; Tidwell RSS; Islam R; Konopleva M; Garcia-Manero G; Ravandi F; Kantarjian HM
Lancet Haematol; 2021 Aug; 8(8):e552-e561. PubMed ID: 34329576
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors.
Bewersdorf JP; Shallis RM; Derkach A; Goldberg AD; Stein A; Stein EM; Marcucci G; Zeidan AM; Shimony S; DeAngelo DJ; Stone RM; Aldoss I; Ball BJ; Stahl M
Leuk Lymphoma; 2023 Jan; 64(1):188-196. PubMed ID: 36287540
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
[TBL] [Abstract][Full Text] [Related]
13. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
[No Abstract] [Full Text] [Related]
14. [Efficacy and Survival of Venetoclax Based Regimen in the Treatment of Acute Myeloid Leukemia].
Kong FC; Qi L; Huang WF; Yu M; Zhou YL; Ji DX; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1676-1683. PubMed ID: 38071045
[TBL] [Abstract][Full Text] [Related]
15. Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia.
Konopleva M; Thirman MJ; Pratz KW; Garcia JS; Recher C; Pullarkat V; Kantarjian HM; DiNardo CD; Dail M; Duan Y; Chyla B; Potluri J; Miller CL; Wei AH
Clin Cancer Res; 2022 Jul; 28(13):2744-2752. PubMed ID: 35063965
[TBL] [Abstract][Full Text] [Related]
16. How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia.
Maiti A; Konopleva MY
Cancer J; 2022 Jan-Feb 01; 28(1):2-13. PubMed ID: 35072368
[TBL] [Abstract][Full Text] [Related]
17. Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study.
Weng G; Huang J; He X; Xue T; Yang L; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Jin H; Liu Q; Du X
Ann Hematol; 2023 Dec; 102(12):3369-3381. PubMed ID: 37723307
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax Plus Gilteritinib for
Daver N; Perl AE; Maly J; Levis M; Ritchie E; Litzow M; McCloskey J; Smith CC; Schiller G; Bradley T; Tiu RV; Naqvi K; Dail M; Brackman D; Siddani S; Wang J; Chyla B; Lee P; Altman JK
J Clin Oncol; 2022 Dec; 40(35):4048-4059. PubMed ID: 35849791
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
Gangat N; Karrar O; Iftikhar M; McCullough K; Johnson IM; Abdelmagid M; Abdallah M; Al-Kali A; Alkhateeb HB; Begna KH; Mangaonkar A; Saliba AN; Hefazi Torghabeh M; Litzow MR; Hogan W; Shah M; Patnaik MM; Pardanani A; Badar T; Murthy H; Foran J; Palmer J; Sproat L; Khera N; Arana Yi C; Tefferi A
Am J Hematol; 2024 Feb; 99(2):193-202. PubMed ID: 38071734
[TBL] [Abstract][Full Text] [Related]
20. Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia.
Zucenka A; Griskevicius L
Br J Haematol; 2024 Apr; 204(4):1227-1231. PubMed ID: 38291741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
